Pigment-Dispersion Syndrome Treatments
Find Pigment-Dispersion Syndrome Treatments
Medications for Pigment-Dispersion Syndrome
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Pigment-Dispersion Syndrome.
Found 15 Approved Drugs for Pigment-Dispersion Syndrome
Timolol
Brand Names
Betimol, Istalol, Timolol GFS, Timoptic, Timoptic-XE
Timolol
Brand Names
Betimol, Istalol, Timolol GFS, Timoptic, Timoptic-XE
Form: Tablet, Solution
Method of administration: Oral, Ophthalmic
FDA approval date: June 08, 1990
Classification: beta-Adrenergic Blocker
Betimol ® is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Latanoprost
Brand Names
Iyuzeh, Xalatan, Xelpros
Latanoprost
Brand Names
Iyuzeh, Xalatan, Xelpros
Form: Solution
Method of administration: Ophthalmic, Topical
FDA approval date: November 15, 2010
IYUZEH ™ (latanoprost ophthalmic solution)
Bimatoprost
Brand Names
Durysta, Latisse, Lumigan, Zolymbus
Bimatoprost
Brand Names
Durysta, Latisse, Lumigan, Zolymbus
Form: Gel, Implant, Solution
Method of administration: Intracameral, Ophthalmic
FDA approval date: January 26, 2009
Classification: Prostaglandin Analog
DURYSTA TM (bimatoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT). DURYSTA TM is a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT). ( 1 )
Cosopt
Generic Name
Dorzolamide
Cosopt
Generic Name
Dorzolamide
Form: Solution
Method of administration: Ophthalmic
FDA approval date: June 01, 2009
Classification: beta-Adrenergic Blocker
COSOPT ® is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering of COSOPT administered twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol administered twice a day and 2% dorzolamide administered three times a day. COSOPT is a combination of dorzolamide hydrochloride, a carbonic anhydrase inhibitor, and timolol maleate, a beta-adrenergic receptor blocking agent, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers. The IOP-lowering of COSOPT twice daily was slightly less than that seen with the concomitant administration of 0.5% timolol twice daily, and 2% dorzolamide three times daily. ( 1 )
Showing 1-5 of 15
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances